|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Das S and Marsden PA: Angiogenesis in
glioblastoma. N Engl J Med. 369:1561–1563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nelson ER, Wardell SE, Jasper JS, Park S,
Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V,
et al: 27-Hydroxycholesterol links hypercholesterolemia and breast
cancer pathophysiology. Science. 342:1094–1098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Norlin M, von Bahr S, Björkhem I and
Wikvall K: On the substrate specificity of human CYP27A1:
Implications for bile acid and cholestanol formation. J Lipid Res.
44:1515–1522. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu DL, Sookthai D, Le Cornet C, Katzke VA,
Johnson TS, Kaaks R and Fortner RT: Reproducibility of serum
oxysterols and lanosterol among postmenopausal women: Results from
EPIC-Heidelberg. Clin Biochem. 52:117–122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Björkhem I: Mechanism of degradation of
the steroid side chain in the formation of bile acids. J Lipid Res.
33:455–471. 1992.PubMed/NCBI
|
|
8
|
Russell DW and Setchell KD: Bile acid
biosynthesis. Biochemistry. 31:4737–4749. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
10
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mao J, Zhang M, Zhong M, Zhang Y and Lv K:
MicroRNA-204, a direct negative regulator of ezrin gene expression,
inhibits glioma cell migration and invasion. Mol Cell Biochem.
396:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kefas B, Godlewski J, Comeau L, Li Y,
Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S and
Purow B: microRNA-7 inhibits the epidermal growth factor receptor
and the Akt pathway and is down-regulated in glioblastoma. Cancer
Res. 68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matusiak D and Benya RV: CYP27A1 and CYP24
expression as a function of malignant transformation in the colon.
J Histochem Cytochem. 55:1257–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu Z, Liu M, Stribinskis V, Klinge CM,
Ramos KS, Colburn NH and Li Y: MicroRNA-21 promotes cell
transformation by targeting the programmed cell death 4 gene.
Oncogene. 27:4373–4379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gangemi RM, Griffero F, Marubbi D, Perera
M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A and Corte G:
SOX2 silencing in glioblastoma tumor-initiating cells causes stop
of proliferation and loss of tumorigenicity. Stem Cells. 27:40–48.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu
Y, Li J, Hasina R, Cheng C, Lingen MW, et al: Network modeling
identifies molecular functions targeted by miR-204 to suppress head
and neck tumor metastasis. PLoS Comput Biol. 6:e10007302010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mikhaylova O, Stratton Y, Hall D, Kellner
E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J and
Czyzyk-Krzeska MF: VHL-regulated MiR-204 suppresses tumor growth
through inhibition of LC3B-mediated autophagy in renal clear cell
carcinoma. Cancer Cell. 21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H,
Li W, Hu B, Cheng SY and Li M: Loss of miR-204 expression enhances
glioma migration and stem cell-like phenotype. Cancer Res.
73:990–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sacconi A, Biagioni F, Canu V, Mori F, Di
Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM,
Germoni S, et al: miR-204 targets Bcl-2 expression and enhances
responsiveness of gastric cancer. Cell Death Dis. 3:e4232012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Wang X and Chen P: miR-204 down
regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal
transition, anoikis resistance and invasion in gastric cancer
cells. BMC Cancer. 13:2902013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chung TK, Lau TS, Cheung TH, Yim SF, Lo
KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, et al: Dysregulation
of microRNA-204 mediates migration and invasion of endometrial
cancer by regulating FOXC1. Int J Cancer. 130:1036–1045. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ryan J, Tivnan A, Fay J, Bryan K, Meehan
M, Creevey L, Lynch J, Bray IM, O'Meara A, Tracey L, et al:
MicroRNA-204 increases sensitivity of neuroblastoma cells to
cisplatin and is associated with a favourable clinical outcome. Br
J Cancer. 107:967–976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
